Optical coherence tomography (OCT) developer NinePoint Medical has received U.S. Food and Drug Administration (FDA) 510(k) clearance for a real-time imaging feature on its NvisionVLE OCT imaging system.
The company's Real-Time Targeting allows physicians to mark areas of interest during volumetric laser endomicroscopy (VLE) procedures, according to the vendor. NinePoint believes this new capability and workflow improvements will enable more accurate targeting of esophageal tissue. The firm said it is initially releasing the real-time feature at a few U.S. hospitals, but it plans to make the feature broadly available later this year.
Beth Israel Deaconess Medical Center in Boston was the first institution to perform procedures using Real-Time Targeting, NinePoint said.
